HE4 is correlated with poor prognostic factors, including stage, myometrial invasion and lymph node metastases, which means it could be used to guide decisions regarding the extent of surgery and need for adjuvant therapy. The gene discussed is WFDC2; the disease is metastatic malignant neoplasm in the lymph nodes.